98%
921
2 minutes
20
Background: An early catheter ablation treatment strategy is effective for rhythm control in patients with atrial fibrillation (AF). In clinical practice, most patients undergo catheter ablation as a second-line treatment, following a trial of antiarrhythmic drugs (AADs). We aimed to investigate the effectiveness and safety of AF catheter ablation performed as a first-line vs a second-line approach, based on data from the nationwide, multicentre Israeli Catheter Ablation Registry.
Methods: Following AF catheter ablation, patients were stratified into 2 groups-first-line vs second-line therapy approaches. The second-line group included AF patients who were referred for catheter ablation following treatment with at least one AAD. The primary endpoint was the 1-year freedom from AF recurrence. The secondary endpoints included 1-year hospitalizations, death, cerebrovascular events, and the composite of adverse cardiac events.
Results: The 923 participants had a mean age of 66 ± 4.5 years. Catheter ablation was performed as a first-line therapy in 192 patients (20.8%). Median times from AF diagnosis to catheter ablation were 1.5 and 3 years in the first- and second-line groups, respectively. Patients in the first-line group were younger, had a shorter AF duration, and more frequently had a normal left atrial size prior to the procedure. The primary endpoint of AF recurrence at 1 year did not differ significantly between the groups (24.9% vs 30%, = 0.205). No significant differences in the incidence of secondary outcomes occurred.
Conclusions: Mildly delayed AF catheter ablation for patients with AF did not compromise the procedure's efficacy or safety.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105751 | PMC |
http://dx.doi.org/10.1016/j.cjco.2025.01.014 | DOI Listing |
J Cardiovasc Electrophysiol
September 2025
Department of Cardiology, Stefan Cardinal Wyszynski Province Specialist Hospital, Lublin, Poland.
Introduction: Wave speed (WS) mapping, enabled by omnipolar technology, allows for real-time visualization of local conduction velocity (CV). Its utility in ventricular tachycardia (VT) ablation has not been fully characterized.
Methods And Results: We describe a case series of patients undergoing VT ablation in which WS mapping was applied alongside established techniques such as peak frequency (PF) mapping and isochronal late activation mapping (ILAM).
J Cardiovasc Electrophysiol
September 2025
Department of Internal Medicine, Division of Cardiology, American University of Beirut Medical Center, Beirut, Lebanon.
Europace
September 2025
Department of Cardiology and Vascular Medicine, University Heart and Vascular Center Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
Background And Aims: Aim of this study was to assess the risk of hemolysis, the extent of myocardial and neural injury after monopolar, monophasic pulsed field ablation (PFA) using a lattice-tip catheter in comparison to single-shot PF ablation platforms employing bipolar, biphasic waveforms.
Methods: This prospective study included consecutive patients undergoing PFA for atrial fibrillation (AF) using the Affera™ mapping and ablation system (n=40). Biomarkers for hemolysis (haptoglobin, LDH, bilirubin), myocardial injury (high-sensitive troponin T, CK, CK-MB), neurocardiac injury (S100), and renal function (creatinine) were assessed pre- and within 24 hours post-ablation.
Heart Rhythm
September 2025
Translational Cardiology Group, Health Research Institute, Santiago de Compostela, Spain; CIBERCV, Madrid, España. Electronic address:
Background: High % of low-voltage area (LVA), a surrogate of scar, is associated with atrial fibrillation (AF) recurrence after pulmonary vein isolation (PVI). Noninvasive biomarkers of LVA are a medical need for PVI decision.
Objective: We aimed to identify the proteome profile of plasma extracellular vesicles (EVs) associated with high % LVA, their cellular origin, and their regulation by hyperglycemia.
BMJ Open
September 2025
Arrhythmia Center, Chinese Academy of Medical Sciences Fuwai Hospital, Beijing, China.
Objectives: To evaluate the efficacy and safety of adding Superior Vena Cava Isolation (SVCI) to Pulmonary Vein Isolation (PVI) in patients with drug-refractory paroxysmal atrial fibrillation (PAF).
Design: Systematic review and meta-analysis of randomised controlled trials (RCTs) using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach, supplemented with Trial Sequential Analysis (TSA) to assess evidence sufficiency.
Data Sources: We searched PubMed, EMBASE, the Cochrane Library (CENTRAL) and Web of Science for relevant studies published up to 13 July 2025.